Astellas Oncology presents data at 2016 ASCO annual meeting
The data specifically apply to ASP8273. It is designed to help patients who have an EGFR mutation positive non-small cell lung cancer (NCSLC). It evaluates the gilteritinib pharmacokinetics as well as pharmacodynamics for patients who have relapse or refractory acute myeloid leukemia.
The data also include information about two investigational antibody drug conjugates for patients who have metastatic urothelial cancer.
"Our activity at this year's ASCO annual meeting underscores our immense commitment to helping those living with cancer," Stephen Eck, vice president and interim head of global oncology development at Astellas, said. "Building on our foundation in non-small cell lung, pancreatic and advanced prostate cancers, we are continuously focused on identifying innovative ways to address the unmet needs of patients and caregivers facing cancer every day."
The annual meeting was hosted in Chicago from June 3 to 7 this year; it included a variety of abstracts from several different companies.
Researchers included Helena Yu from Memorial Sloan Ketting Cancer Center, Catherine Smith from the University of California San Francisco, Daniel Petrlak from Yale University, and Jonathan Rosenberg from Memorial Sloan Kettering Cancer Center.
Organizations in this story
Astellas Pharma US, Inc. 1 Astellas Way Northbrook, IL - 60062